Rapamycin (Sirolimus) Compassionate Use and Expanded Access: What Women Need to Know in 2026

What Is Rapamycin and Why Are Women Asking About It?

Sirolimus, sold under the brand name Rapamune by Pfizer and available in multiple generic forms, is an mTOR inhibitor originally developed as an immunosuppressant for organ transplant recipients. The FDA approved it for kidney transplant rejection prophylaxis and, later, for lymphangioleiomyomatosis (LAM), a rare lung disease that disproportionately affects women of reproductive age.

In 2026, women are asking about it for entirely different reasons. The longevity research community has built substantial interest around rapamycin's ability to extend lifespan in every model organism tested, including the 2009 NIA Interventions Testing Program finding that rapamycin extended median lifespan in mice by 9-14% even when started late in life. Clinicians working at the intersection of metabolic health and aging have since moved this into human off-label practice, with doses far below transplant-level immunosuppression.

For women specifically, the interest spans several conditions.

Why This Drug Lands Differently for Women

Women with polycystic ovary syndrome (PCOS) have elevated mTOR signaling in ovarian tissue, and early research suggests sirolimus may help normalize that pathway. Women in perimenopause and post-menopause face accelerating metabolic change driven partly by mTOR dysregulation as estrogen falls. Women with LAM, the only female-predominant lung disease with an FDA-approved mTOR inhibitor treatment, may already be on sirolimus and need to understand access options as their coverage changes.

The MILES trial established sirolimus 2 mg/day as the standard LAM dose, and that trial enrolled only women. It is one of the few sirolimus trials conducted exclusively in a female population, giving us meaningful sex-specific safety data that most longevity trials lack entirely. Outside LAM and transplant, the human trial data in women is thin. That is an honest gap worth naming.

mTOR, Hormones, and the Female Metabolic Picture

MTOR complex 1 (mTORC1) sits at a crossroads between insulin signaling, reproductive hormones, and cellular aging. Estrogen modulates mTORC1 activity, which partly explains why metabolic disease accelerates after menopause. Research from the Mayo Clinic's Robert and Arlene Kogod Center on Aging has documented sex differences in rapamycin pharmacokinetics, with women showing different blood-level profiles at the same mg/kg dose. This is directly relevant to dosing decisions your prescriber should make, and it is not yet reflected in standard package insert guidance.

FDA Expanded Access and Compassionate Use: The Real Pathway

Expanded access, often called compassionate use, is the FDA mechanism allowing patients outside a clinical trial to receive an investigational or unapproved use of a drug. For rapamycin, this pathway is more nuanced than for a true investigational drug, because sirolimus is already FDA-approved. That changes the access calculus significantly.

When Expanded Access Applies to Sirolimus

Because sirolimus is an approved drug, the FDA does not require an expanded access IND (Investigational New Drug application) simply to prescribe it off-label. A licensed physician in the United States can legally write a prescription for sirolimus for any indication they judge to be medically appropriate. The FDA's off-label prescribing guidance makes this explicit: approved drugs may be prescribed off-label, and no special FDA application is needed.

Formal expanded access applications under 21 CFR Part 312 Subpart I become relevant when a physician wants to use sirolimus in a way that requires a new IND, for example within an unapproved combination protocol at a research institution, or when obtaining institutional IRB oversight for a single-patient protocol.

The practical takeaway: you do not need a compassionate use application to get an off-label sirolimus prescription. You need a physician willing to prescribe it off-label and a pharmacy willing to fill it.

How to Apply for Individual Patient Expanded Access (If You Do Need It)

For situations that do require formal expanded access, such as an unapproved sirolimus analog, a pediatric case with no prescribing precedent, or an institutional research protocol, the process works as follows.

1. A physician must submit FDA Form 3926 for individual patient expanded access.
2. The FDA typically responds within 24 hours for life-threatening situations and within 30 days for non-emergency requests.
3. The treating physician must have an IND or sponsor one.
4. FDA's expanded access database lists programs by drug and condition where a manufacturer has an open expanded access program.

As of early 2026, Pfizer does not maintain a public open expanded access program for Rapamune outside its approved indications. Generic manufacturers likewise do not run formal expanded access programs. This means your route to sirolimus for longevity or metabolic health is almost always the off-label prescription pathway, not a formal compassionate use application.

How to Get Rapamycin Prescribed Off-Label

Finding a Prescriber

The growth of longevity medicine has produced a small but expanding cohort of physicians who prescribe low-dose rapamycin off-label. Relevant specialties include internal medicine physicians with a longevity focus, endocrinologists managing metabolic disease, and women's health practitioners who have reviewed the emerging data.

Telehealth platforms that focus on longevity medicine have made access meaningfully faster than it was even two years ago. A typical new-patient visit involves reviewing bloodwork, body composition data, and any relevant history, and the visit can take place virtually in most U.S. States. Programs change frequently, so verifying current availability directly with platforms is necessary.

No national medical society, including ACOG, The Menopause Society, or ASRM, has issued a formal position endorsing off-label rapamycin for women's health indications as of 2026. That is worth knowing before you start.

What a Prescriber Should Review Before Writing the Prescription

A responsible off-label rapamycin workup for a woman includes, at minimum: a complete metabolic panel, fasting lipids (sirolimus causes dyslipidemia in a meaningful proportion of patients), CBC, and a pregnancy test or confirmed contraception plan. The MILES trial documented hypertriglyceridemia in 45% of LAM patients on sirolimus 2 mg/day, a rate relevant even at lower longevity doses.

Menstrual cycle history matters. Sirolimus can disrupt menstrual regularity and has been associated with amenorrhea and irregular cycles in transplant recipients. This is underreported in longevity discussions and should be part of your informed consent conversation.

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety Information

Sirolimus is contraindicated in pregnancy. This is not a soft caution. Animal reproductive studies show embryotoxicity and fetal toxicity at doses below the human equivalent. The FDA-approved Rapamune labeling classifies sirolimus as causing fetal harm and states that women of childbearing potential must use effective contraception before starting therapy, during therapy, and for 12 weeks after stopping sirolimus.

Twelve Weeks of Contraception After Stopping

That 12-week post-treatment contraception window is clinically significant and poorly understood by many women who encounter rapamycin through longevity content. Sirolimus has a half-life of approximately 62 hours in healthy adults, but its pharmacodynamic effects on cellular processes persist beyond plasma clearance. The prescribing information requires 12 weeks of reliable contraception after the last dose before pregnancy is considered safe.

Lactation Transfer

Sirolimus is present in human breast milk. The NIH LactMed database notes that sirolimus transfers into breast milk and that the potential for serious adverse effects in a nursing infant means breastfeeding is not recommended during sirolimus therapy. If you are postpartum and breastfeeding, this drug is not appropriate until you have weaned.

Life-Stage Summary Table

| Life Stage | Rapamycin Use | |---|---| | Reproductive years (not using contraception) | Contraindicated | | Reproductive years (on reliable contraception) | Off-label use possible; cycle changes possible | | Trying to conceive | Contraindicated; stop 12 weeks before attempting pregnancy | | Pregnancy | Contraindicated | | Postpartum / breastfeeding | Not recommended | | Perimenopause | Off-label use possible; lipid monitoring required | | Post-menopause | Off-label use possible; no contraception requirement |

How to Get Sirolimus Cheaper: Discount Programs, Generics, and Insurance

Sirolimus is expensive at brand-name pricing. Rapamune 1 mg tablets can cost more than $800 per month at retail without insurance. The good news for women seeking access is that generic sirolimus is widely available and often costs a fraction of the brand price.

Generic Sirolimus

Multiple manufacturers produce FDA-approved generic sirolimus, including tablets in 0.5 mg, 1 mg, and 2 mg strengths, as well as a 1 mg/mL oral solution. At major pharmacy chains, a 30-tablet supply of generic sirolimus 1 mg can be found for $40-$120 with discount programs, depending on the pharmacy and geographic location.

GoodRx and Other Discount Cards

GoodRx and similar pharmacy benefit cards consistently reduce the retail price of generic sirolimus significantly. Prices fluctuate by pharmacy and ZIP code. Checking current pricing directly on the GoodRx platform before choosing a pharmacy is the most reliable approach, as prices change week to week.

Manufacturer Assistance: Pfizer's RxPathways Program

Pfizer operates the RxPathways program for Rapamune, which provides brand-name drug assistance for patients who meet income eligibility criteria and lack adequate prescription coverage. As of 2026, eligibility thresholds and application processes are subject to change; verifying current requirements directly on the Pfizer site is necessary.

Generic manufacturers typically do not run patient assistance programs equivalent to brand programs, but state pharmaceutical assistance programs and nonprofit organizations like the Patient Advocate Foundation's Co-Pay Relief program may fill gaps for women using sirolimus for an FDA-approved indication such as LAM.

Compounding Pharmacies

Some longevity medicine practices direct patients to compounding pharmacies that prepare sirolimus in custom doses, particularly for the low-dose weekly protocols studied in aging research. Compounded sirolimus is not FDA-approved and does not carry the same quality assurance as commercially manufactured generics. The FDA has issued guidance on compounding that consumers should review. For most women, the commercially available generic 1 mg tablet taken weekly is a more straightforward option than a compounded preparation.

Insurance Coverage

Insurance coverage for sirolimus depends entirely on the diagnosis code attached to the prescription. For LAM (ICD-10 J84.81) and kidney transplant rejection prophylaxis, coverage is generally available under most commercial plans and Medicare Part D. For off-label longevity use, insurance will not cover the prescription, and you should plan for out-of-pocket costs.

Can You Use HSA or FSA Funds for Rapamycin?

Yes, with conditions. Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay for prescription medications, including sirolimus, when the drug is prescribed by a licensed healthcare provider for a medical purpose. The IRS Publication 502 governs qualifying medical expenses, and prescription drugs are eligible expenses regardless of whether the indication is FDA-approved or off-label, provided a valid prescription exists.

What the IRS does not allow is using HSA/FSA funds for drugs taken purely for general wellness with no medical diagnosis attached to the prescription. If your prescriber has documented a clinical indication, such as metabolic syndrome, insulin resistance, LAM, or another qualifying condition, your pharmacist can run the transaction through your HSA or FSA card at the point of sale.

Keep your prescription documentation and any clinical notes in your records. HSA and FSA administrators occasionally request documentation for high-cost medications, and having the prescription on file protects you in an audit.

Who This Is Right For and Who Should Avoid It

Women Who May Be Appropriate Candidates for Off-Label Sirolimus

Post-menopausal women with documented metabolic disease, such as prediabetes, elevated fasting insulin, or central adiposity, who have not responded adequately to lifestyle intervention and who have a clinician willing to prescribe and monitor represent the population most often discussed in longevity medicine circles. Women with confirmed LAM who need to understand their prescription access options are a separate, distinct group with strong FDA-approved clinical rationale.

Women with PCOS who have insulin resistance as a dominant feature are an emerging population of interest in the research literature, though no randomized controlled trial has established sirolimus as a PCOS treatment.

A practical framework for thinking about off-label sirolimus candidacy in women across life stages:

Most likely to have a clinician willing to prescribe:

• Post-menopausal, not pregnant, not breastfeeding, lipids and renal function normal at baseline
• Established patient with a longevity medicine or endocrinology practice
• Willing to monitor: lipid panel and CBC every 3 months for the first year

Requires additional conversation and monitoring:

• Perimenopausal women with irregular cycles (sirolimus may worsen cycle irregularity)
• Women with any immunocompromising condition or history of serious infection
• Women taking CYP3A4 inhibitors such as fluconazole, which can substantially raise sirolimus blood levels

Not appropriate candidates:

• Currently pregnant or planning pregnancy within 12 weeks
• Breastfeeding
• Active serious infection
• Women with a history of impaired wound healing who may need surgery

Conditions Where Sirolimus Has Female-Specific Clinical Data

Lymphangioleiomyomatosis is the clearest case: TSC-LAM and sporadic LAM both respond to sirolimus, the condition occurs almost exclusively in women, and the MILES trial enrolled 89 women. This is where the evidence base for sirolimus in women is strongest. For all other off-label uses, you are largely extrapolating from either male-dominated trials or animal models.

Monitoring: What Labs Women Need on Sirolimus

Because sirolimus carries real risks at any dose, monitoring is not optional. The MILES trial protocol and standard transplant medicine practice both support the following monitoring schedule adapted for lower off-label doses:

Baseline Before Starting

• Complete metabolic panel (renal function, liver enzymes)
• Fasting lipid panel
• CBC with differential
• Pregnancy test or documented reliable contraception
• HbA1c if metabolic indication is present

Ongoing Monitoring

• Lipid panel and CBC at 3 months, then every 6 months if stable
• Trough sirolimus level at 2 weeks after starting or any dose change (target trough for longevity protocols in clinical practice is typically 3-7 ng/mL, substantially below transplant targets of 10-20 ng/mL, though this is not standardized)
• Blood pressure at every visit: sirolimus can raise blood pressure
• Menstrual cycle history at every visit if premenopausal

Drug Interactions Women Should Know About

Sirolimus is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Several medications commonly used by women have significant interaction potential.

Azole antifungals (fluconazole, voriconazole, ketoconazole): These are potent CYP3A4 inhibitors that can raise sirolimus blood levels several-fold. Fluconazole is frequently prescribed to women for vaginal candidiasis. A single-dose fluconazole while on weekly sirolimus may be clinically significant. Inform any prescriber writing you fluconazole that you are taking sirolimus.

Hormonal contraceptives: Ethinyl estradiol-containing oral contraceptives are metabolized by CYP3A4. Interaction data between sirolimus and combined oral contraceptives is limited. Given that reliable contraception is mandatory, this interaction should be discussed with your prescriber when selecting a contraceptive method.

St. John's Wort: This common supplement is a strong CYP3A4 inducer and can substantially reduce sirolimus levels. Women using it for mood support during perimenopause should stop before starting sirolimus.

Current Clinical Trials Enrolling Women

As of early 2026, several trials are actively investigating rapamycin in populations that include or focus on women.

The PEARL trial (Prevention of Alzheimer's with Rapamycin and Longevity) at the University of Texas Health Science Center San Antonio is among the most watched human rapamycin trials, with sex-stratified analysis planned. Women interested in accessing sirolimus through a clinical trial rather than off-label prescription can search ClinicalTrials.gov using "sirolimus" and their specific condition to find actively enrolling studies. Trial participation provides the drug at no cost, physician monitoring, and contributes to the evidence base women need.